

# Scott A North

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9301416/publications.pdf>

Version: 2024-02-01

117  
papers

12,966  
citations

76196

40  
h-index

24915

109  
g-index

117  
all docs

117  
docs citations

117  
times ranked

12028  
citing authors

#	ARTICLE	IF	CITATIONS
1	Socioeconomic disparities in the prevalence of comorbid chronic conditions among Canadian adults with cancer. <i>Acta Oncologica</i> , 2022, 61, 294-301.	0.8	0
2	Health-Related Quality of Life in Metastatic, Hormone-Sensitive Prostate Cancer: ENZAMET (ANZUP) Trial. <i>Journal of Clinical Oncology</i> , 2022, 40, 837-846.	0.8	29
3	Cost-effectiveness of enzalutamide versus apalutamide versus androgen deprivation therapy alone for the treatment of metastatic castration-sensitive prostate cancer in Canada. <i>Journal of Medical Economics</i> , 2022, 25, 583-590.	1.0	2
4	The prognostic impact of bone metastasis in patients with metastatic urothelial carcinoma treated with first-line platinum-based chemotherapy. <i>Therapeutic Advances in Medical Oncology</i> , 2022, 14, 175883592210948.	1.4	2
5	Updated overall survival outcomes in ENZAMET (ANZUP 1304), an international, cooperative group trial of enzalutamide in metastatic hormone-sensitive prostate cancer (mHSPC). <i>Journal of Clinical Oncology</i> , 2022, 40, LBA5004-LBA5004.	0.8	29
6	Comparative effectiveness of neoadjuvant chemotherapy in bladder and upper urinary tract urothelial carcinoma. <i>BJU International</i> , 2021, 127, 528-537.	1.3	10
7	Defining cisplatin eligibility in patients with muscle-invasive bladder cancer. <i>Nature Reviews Urology</i> , 2021, 18, 104-114.	1.9	57
8	Patterns of cost-related medication underuse among Canadian adults with cancer: a cross-sectional study using survey data. <i>CMAJ Open</i> , 2021, 9, E474-E481.	1.1	3
9	The Rapidly Evolving Landscape of First-Line Targeted Therapy in Metastatic Urothelial Cancer: A Systematic Review. <i>Oncologist</i> , 2021, 26, e1381-e1394.	1.9	8
10	Association of age with response to preoperative chemotherapy in patients with muscle-invasive bladder cancer. <i>World Journal of Urology</i> , 2021, 39, 4345-4354.	1.2	4
11	Stereotactic Radiotherapy for Oligoprogression in Metastatic Renal Cell Cancer Patients Receiving Tyrosine Kinase Inhibitor Therapy: A Phase 2 Prospective Multicenter Study. <i>European Urology</i> , 2021, 80, 693-700.	0.9	65
12	Overall Survival of Men with Metachronous Metastatic Hormone-sensitive Prostate Cancer Treated with Enzalutamide and Androgen Deprivation Therapy. <i>European Urology</i> , 2021, 80, 275-279.	0.9	28
13	The prognostic value of the neutrophil-to-lymphocyte ratio in patients with muscle-invasive bladder cancer treated with neoadjuvant chemotherapy and radical cystectomy. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2020, 38, 3.e17-3.e27.	0.8	29
14	Eligibility Criteria and Endpoints in Metastatic Renal Cell Carcinoma Trials. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2020, 43, 559-566.	0.6	3
15	Optimizing management of advanced urothelial carcinoma: A review of emerging therapies and biomarker-driven patient selection. <i>Canadian Urological Association Journal</i> , 2020, 14, E373-E382.	0.3	8
16	Current Management of Localized Muscle-Invasive Bladder Cancer: Consensus Guideline from the Genitourinary Medical Oncologists of Canada. <i>Bladder Cancer</i> , 2020, 6, 363-392.	0.2	1
17	Impact of sex on response to neoadjuvant chemotherapy in patients with bladder cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2020, 38, 639.e1-639.e9.	0.8	15
18	2021 Canadian Urological Association (CUA)-Canadian Uro Oncology Group (CUOG) guideline: Management of castration-resistant prostate cancer (CRPC) (full-text). <i>Canadian Urological Association Journal</i> , 2020, 15, E81-9.	0.3	10

#	ARTICLE	IF	CITATIONS
19	Management of advanced kidney cancer: Kidney Cancer Research Network of Canada (KCRNC) consensus update 2021. Canadian Urological Association Journal, 2020, 15, 84-97.	0.3	11
20	Activating AKT1 and PIK3CA Mutations in Metastatic Castration-Resistant Prostate Cancer. European Urology, 2020, 78, 834-844.	0.9	47
21	Real world evidence: Abiraterone use post-docetaxel in metastatic castrate-resistant prostate cancer. Journal of Oncology Pharmacy Practice, 2019, 25, 1293-1300.	0.5	3
22	Management of urachal cancer: A review by the Canadian Urological Association and Genitourinary Medical Oncologists of Canada. Canadian Urological Association Journal, 2019, 14, E57-E64.	0.3	26
23	2019 Canadian Urological Association (CUA)-Canadian Uro Oncology Group (CUOG) guidelines for the management of castration-resistant prostate cancer (CRPC). Canadian Urological Association Journal, 2019, 13, 307-314.	0.3	21
24	Management of Advanced Kidney Cancer: Kidney Cancer Research Network of Canada (KCRNC) consensus update 2019. Canadian Urological Association Journal, 2019, 13, 343-54.	0.3	10
25	Enzalutamide with Standard First-Line Therapy in Metastatic Prostate Cancer. New England Journal of Medicine, 2019, 381, 121-131.	13.9	982
26	Canadian Urological Association/Genitourinary Medical Oncologists of Canada consensus statement: Management of unresectable locally advanced and metastatic urothelial carcinoma. Canadian Urological Association Journal, 2019, 13, 318-327.	0.3	8
27	A Phase II Study of PX-866 in Patients With Recurrent or Metastatic Castration-resistant Prostate Cancer: Canadian Cancer Trials Group Study IND205. Clinical Genitourinary Cancer, 2019, 17, 201-208.e1.	0.9	29
28	Continuing towards optimization of bladder cancer care in Canada: Summary of the 3rd BCC-CUA-CUOG bladder cancer quality of care consensus meeting. Canadian Urological Association Journal, 2019, 14, E115-E125.	0.3	3
29	Cytoreductive Nephrectomy in Metastatic Papillary Renal Cell Carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database Consortium. European Urology Oncology, 2019, 2, 643-648.	2.6	31
30	The efficacy and safety of sunitinib given on an individualised schedule as first-line therapy for metastatic renal cell carcinoma: A phase 2 clinical trial. European Journal of Cancer, 2019, 108, 69-77.	1.3	25
31	Development and Implementation of a Continuing Medical Education Program in Canada: Knowledge Translation for Renal Cell Carcinoma (KT4RCC). Journal of Cancer Education, 2019, 34, 14-18.	0.6	0
32	Real-world Outcomes in Advanced Urothelial Cancer and the Role of Neutrophil to Lymphocyte Ratio. Clinical Genitourinary Cancer, 2018, 16, e637-e644.	0.9	6
33	High fat mass associates with occurrence of targeted therapy-induced left ventricular ejection fraction reduction in patients with renal cell carcinoma. Clinical Nutrition, 2018, 37, 1070-1072.	2.3	1
34	Screen Failure Rates in Contemporary Randomized Clinical Phase II/III Therapeutic Trials in Genitourinary Malignancies. Clinical Genitourinary Cancer, 2018, 16, e233-e242.	0.9	8
35	Improving patient journey and quality of care: Summary from the second Bladder Cancer Canada-Canadian Urological Association- Canadian Urologic Oncology Group (BCC-CUA-CUOG) bladder cancer quality of care consensus meeting. Canadian Urological Association Journal, 2018, 12, E281-97.	0.3	9
36	Effects of high-intensity interval training on fatigue and quality of life in testicular cancer survivors. British Journal of Cancer, 2018, 118, 1313-1321.	2.9	70

#	ARTICLE	IF	CITATIONS
37	The Prognostic Role of the Change in Neutrophil-to-Lymphocyte Ratio During Neoadjuvant Chemotherapy in Patients with Muscle-Invasive Bladder Cancer: A Retrospective, Multi-Institutional Study. <i>Bladder Cancer</i> , 2018, 4, 185-194.	0.2	19
38	A randomized phase II study of pelareorep and docetaxel or docetaxel alone in men with metastatic castration resistant prostate cancer: CCTG study IND 209. <i>Oncotarget</i> , 2018, 9, 8155-8164.	0.8	18
39	Quality indicators in the management of bladder cancer: A modified Delphi study. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2017, 35, 328-334.	0.8	29
40	Discontinuing VEGF-targeted Therapy for Progression Versus Toxicity Affects Outcomes of Second-line Therapies in Metastatic Renal Cell Carcinoma. <i>Clinical Genitourinary Cancer</i> , 2017, 15, 403-410.e2.	0.9	14
41	Impact of Molecular Subtypes in Muscle-invasive Bladder Cancer on Predicting Response and Survival after Neoadjuvant Chemotherapy. <i>European Urology</i> , 2017, 72, 544-554.	0.9	638
42	Effects of high-intensity aerobic interval training on cardiovascular disease risk in testicular cancer survivors: A phase 2 randomized controlled trial. <i>Cancer</i> , 2017, 123, 4057-4065.	2.0	74
43	Circulating Tumor DNA Reveals Clinically Actionable Somatic Genome of Metastatic Bladder Cancer. <i>Clinical Cancer Research</i> , 2017, 23, 6487-6497.	3.2	121
44	The role of the built environment in a randomized controlled trial to increase physical activity among men with prostate cancer: the PROMOTE trial. <i>Supportive Care in Cancer</i> , 2017, 25, 2993-2996.	1.0	5
45	First-line sunitinib or pazopanib in metastatic renal cell carcinoma: The Canadian experience. <i>Canadian Urological Association Journal</i> , 2017, 11, 112.	0.3	32
46	Management of advanced kidney cancer: Canadian Kidney Cancer Forum (CKCF) consensus update 2017. <i>Canadian Urological Association Journal</i> , 2017, 11, 310-320.	0.3	6
47	Randomized, Noncomparative, Phase II Trial of Early Switch From Docetaxel to Cabazitaxel or Vice Versa, With Integrated Biomarker Analysis, in Men With Chemotherapy-Naïve, Metastatic, Castration-Resistant Prostate Cancer. <i>Journal of Clinical Oncology</i> , 2017, 35, 3181-3188.	0.8	73
48	Risk factors and model for predicting toxicity-related treatment discontinuation in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted therapy: Results from the International Metastatic Renal Cell Carcinoma Database Consortium. <i>Cancer</i> , 2016, 122, 411-419.	2.0	27
49	Cisplatin- Versus Non-Cisplatin-based First-Line Chemotherapy for Advanced Urothelial Carcinoma Previously Treated With Perioperative Cisplatin. <i>Clinical Genitourinary Cancer</i> , 2016, 14, 331-340.	0.9	12
50	Sunitinib maintenance therapy after response to docetaxel in metastatic castration resistant prostate cancer (mCRPC). <i>Investigational New Drugs</i> , 2016, 34, 771-776.	1.2	4
51	Social-ecological correlates of physical activity in kidney cancer survivors. <i>Journal of Cancer Survivorship</i> , 2016, 10, 164-175.	1.5	20
52	Recommendations for the improvement of bladder cancer quality of care in Canada: A consensus document reviewed and endorsed by Bladder Cancer Canada (BCC), Canadian Urologic Oncology Group (CUOG), and Canadian Urological Association (CUA), December 2015. <i>Canadian Urological Association Journal</i> , 2016, 10, 46.	0.3	55
53	Assessing the utility of cabazitaxel in mCRPC. <i>Canadian Urological Association Journal</i> , 2016, 10, 111.	0.3	0
54	Perioperative chemotherapy for muscle invasive bladder cancer. <i>Current Opinion in Supportive and Palliative Care</i> , 2015, 9, 249-254.	0.5	1

#	ARTICLE	IF	CITATIONS
55	Food effects on abiraterone pharmacokinetics in healthy subjects and patients with metastatic castration-resistant prostate cancer. <i>Journal of Clinical Pharmacology</i> , 2015, 55, 1406-1414.	1.0	78
56	Changes in motivational outcomes following a supervised physical activity program with behavioral counseling in kidney cancer survivors: a pilot study. <i>Psycho-Oncology</i> , 2015, 24, 1204-1207.	1.0	4
57	Management of advanced kidney cancer: Canadian Kidney Cancer Forum consensus update. <i>Canadian Urological Association Journal</i> , 2015, 9, 164.	0.3	18
58	Impact of Bone-targeted Therapies in Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer Patients Treated with Abiraterone Acetate: Post Hoc Analysis of Study COU-AA-302. <i>European Urology</i> , 2015, 68, 570-577.	0.9	50
59	Multicenter Assessment of Neoadjuvant Chemotherapy for Muscle-invasive Bladder Cancer. <i>European Urology</i> , 2015, 67, 241-249.	0.9	235
60	The 2014 CUA-CUOG Guidelines for the Management of Castration Resistant Prostate Cancer (CRPC). <i>Canadian Urological Association Journal</i> , 2015, 9, 90.	0.3	82
61	Outcome of Patients With Metastatic Sarcomatoid Renal Cell Carcinoma: Results From the International Metastatic Renal Cell Carcinoma Database Consortium. <i>Clinical Genitourinary Cancer</i> , 2015, 13, e79-e85.	0.9	78
62	Characteristics of Long-Term and Short-Term Survivors of Metastatic Renal Cell Carcinoma Treated With Targeted Therapies: Results From the International mRCC Database Consortium. <i>Clinical Genitourinary Cancer</i> , 2015, 13, 150-155.	0.9	10
63	Improving the outcome of patients with muscle invasive urothelial carcinoma of the bladder with neoadjuvant gemcitabine/cisplatin chemotherapy: A single institution experience. <i>Canadian Urological Association Journal</i> , 2014, 8, 287.	0.3	11
64	A multicentre analysis of abiraterone acetate in Canadian patients with metastatic castration resistant prostate cancer. <i>Canadian Urological Association Journal</i> , 2014, 8, 583.	0.3	7
65	Feasibility and Preliminary Efficacy of Adding Behavioral Counseling to Supervised Physical Activity in Kidney Cancer Survivors. <i>Cancer Nursing</i> , 2014, 37, E8-E22.	0.7	13
66	Treatment of muscle-invasive bladder cancer in Canada: A survey of genitourinary medical oncologists and urologists. <i>Canadian Urological Association Journal</i> , 2014, 8, 309.	0.3	12
67	Efficacy of Targeted Therapy for Metastatic Renal Cell Carcinoma in the Elderly Patient Population. <i>Clinical Genitourinary Cancer</i> , 2014, 12, 354-358.	0.9	26
68	First-Line Mammalian Target of Rapamycin Inhibition in Metastatic Renal Cell Carcinoma: An Analysis of Practice Patterns From the International Metastatic Renal Cell Carcinoma Database Consortium. <i>Clinical Genitourinary Cancer</i> , 2014, 12, 335-340.	0.9	9
69	Updated Interim Efficacy Analysis and Long-term Safety of Abiraterone Acetate in Metastatic Castration-resistant Prostate Cancer Patients Without Prior Chemotherapy (COU-AA-302). <i>European Urology</i> , 2014, 66, 815-825.	0.9	221
70	Expression of Nucleoside Transporters and Deoxycytidine Kinase Proteins in Muscle Invasive Urothelial Carcinoma of the Bladder: Correlation with Pathological Response to Neoadjuvant Platinum/Gemcitabine Combination Chemotherapy. <i>Journal of Urology</i> , 2014, 191, 35-39.	0.2	6
71	The Impact of Low Serum Sodium on Treatment Outcome of Targeted Therapy in Metastatic Renal Cell Carcinoma: Results from the International Metastatic Renal Cell Cancer Database Consortium. <i>European Urology</i> , 2014, 65, 723-730.	0.9	69
72	A Population-Based Overview of Sequences of Targeted Therapy in Metastatic Renal Cell Carcinoma. <i>Clinical Genitourinary Cancer</i> , 2014, 12, e127-e131.	0.9	25

#	ARTICLE	IF	CITATIONS
73	Survival Outcome and Treatment Response of Patients with Late Relapse from Renal Cell Carcinoma in the Era of Targeted Therapy. <i>European Urology</i> , 2014, 65, 1086-1092.	0.9	71
74	Randomized Controlled Trial of a Behavior Change Intervention to Increase Physical Activity and Quality of Life in Prostate Cancer Survivors. <i>Annals of Behavioral Medicine</i> , 2013, 46, 382-393.	1.7	34
75	The association of clinical outcome to first-line VEGF-targeted therapy with clinical outcome to second-line VEGF-targeted therapy in metastatic renal cell carcinoma patients. <i>Targeted Oncology</i> , 2013, 8, 203-209.	1.7	47
76	Metastatic non-“clear cell renal cell carcinoma treated with targeted therapy agents: Characterization of survival outcome and application of the International mRCC Database Consortium criteria. <i>Cancer</i> , 2013, 119, 2999-3006.	2.0	189
77	Prognostic Factors of Survival for Patients With Metastatic Renal Cell Carcinoma With Brain Metastases Treated With Targeted Therapy: Results From the International Metastatic Renal Cell Carcinoma Database Consortium. <i>Clinical Genitourinary Cancer</i> , 2013, 11, 311-315.	0.9	64
78	Associations between sitting time and quality of life in a population-based sample of kidney cancer survivors. <i>Mental Health and Physical Activity</i> , 2013, 6, 16-23.	0.9	13
79	Intermittent LHRH Therapy in the Management of Castrate-resistant Prostate Cancer (CRPCa). <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2013, 36, 601-605.	0.6	11
80	CUA-CUOG Guidelines for the Management of Castration Resistant Prostate Cancer (CRPC): 2013 Update. <i>Canadian Urological Association Journal</i> , 2013, 7, 231.	0.3	15
81	Neoadjuvant chemotherapy (NC) should be administered to fit patients with newly diagnosed, potentially resectable muscle-invasive urothelial cancer (MIUC) of the bladder “ A 2013 CAGMO Consensus Statement and Call for a Streamlined Referral Process. <i>Canadian Urological Association Journal</i> , 2013, 7, 312.	0.3	18
82	Management of Advanced Kidney Cancer “ Canadian Kidney Cancer Forum Consensus Update. <i>Canadian Urological Association Journal</i> , 2013, 7, 238.	0.3	7
83	A population-based study examining the effect of tyrosine kinase inhibitors on survival in metastatic renal cell carcinoma in Alberta and the role of nephrectomy prior to treatment. <i>Canadian Urological Association Journal</i> , 2013, 3, 281.	0.3	39
84	Prise en charge du cancer du rein de stade avancé : Mise À jour 2013 des lignes directrices consensuelles du Forum canadien sur le cancer du rein. <i>Canadian Urological Association Journal</i> , 2013, 7, .	0.3	0
85	Management of small cell carcinoma of the bladder: Consensus guidelines from the Canadian Association of Genitourinary Medical Oncologists (CAGMO). <i>Canadian Urological Association Journal</i> , 2013, 7, 44.	0.3	41
86	Why consider neoadjuvant chemotherapy for muscle-invasive transitional cell carcinoma of the bladder?. <i>Canadian Urological Association Journal</i> , 2013, 2, 222.	0.3	6
87	A rapid PSA half-life following docetaxel chemotherapy is associated with improved survival in hormone refractory prostate cancer. <i>Canadian Urological Association Journal</i> , 2013, 3, 369.	0.3	19
88	Correlates of physical activity in a population-based sample of kidney cancer survivors: an application of the theory of planned behavior. <i>International Journal of Behavioral Nutrition and Physical Activity</i> , 2012, 9, 96.	2.0	52
89	Conditional survival of patients with metastatic renal-cell carcinoma treated with VEGF-targeted therapy: a population-based study. <i>Lancet Oncology</i> , The, 2012, 13, 927-935.	5.1	112
90	Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study. <i>Lancet Oncology</i> , The, 2012, 13, 983-992.	5.1	1,182

#	ARTICLE	IF	CITATIONS
91	Effect of abiraterone acetate and prednisone compared with placebo and prednisone on pain control and skeletal-related events in patients with metastatic castration-resistant prostate cancer: exploratory analysis of data from the COU-AA-301 randomised trial. <i>Lancet Oncology</i> , The, 2012, 13, 1210-1217.	5.1	254
92	A phase II study of sorafenib in combination with bicalutamide in patients with chemotherapy-naive castration resistant prostate cancer. <i>Investigational New Drugs</i> , 2012, 30, 1652-1659.	1.2	47
93	Physical activity preferences in a population-based sample of kidney cancer survivors. <i>Supportive Care in Cancer</i> , 2012, 20, 1709-1717.	1.0	37
94	Vascular endothelial growth factor (VEGF) therapy in metastatic renal cell carcinoma (mRCC): Differences between Asian and non-Asian patients.. <i>Journal of Clinical Oncology</i> , 2012, 30, 451-451.	0.8	1
95	Small cell carcinoma of the genitourinary tract: A 10-year single institution experience.. <i>Journal of Clinical Oncology</i> , 2012, 30, 312-312.	0.8	2
96	Abiraterone and Increased Survival in Metastatic Prostate Cancer. <i>New England Journal of Medicine</i> , 2011, 364, 1995-2005.	13.9	3,736
97	The Impact of Cytoreductive Nephrectomy on Survival of Patients With Metastatic Renal Cell Carcinoma Receiving Vascular Endothelial Growth Factor Targeted Therapy. <i>Journal of Urology</i> , 2011, 185, 60-66.	0.2	322
98	Randomized Phase II Trial of Custirsen (OGX-011) in Combination with Docetaxel or Mitoxantrone as Second-line Therapy in Patients with Metastatic Castrate-Resistant Prostate Cancer Progressing after First-line Docetaxel: CUOG Trial P-06c. <i>Clinical Cancer Research</i> , 2011, 17, 5765-5773.	3.2	120
99	Associations Between Physical Activity and Quality of Life in a Population-Based Sample of Kidney Cancer Survivors. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2011, 20, 859-868.	1.1	41
100	A phase II trial of weekly i.v. KW-2170 in advanced castrate-resistant prostate cancer. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2010, 6, 292-297.	0.7	3
101	Randomized Phase II Study of Docetaxel and Prednisone With or Without OGX-011 in Patients With Metastatic Castration-Resistant Prostate Cancer. <i>Journal of Clinical Oncology</i> , 2010, 28, 4247-4254.	0.8	221
102	Clinical Outcome in Metastatic Renal Cell Carcinoma Patients After Failure of Initial Vascular Endothelial Growth Factor-Targeted Therapy. <i>Urology</i> , 2010, 76, 430-434.	0.5	75
103	Prognostic Factors for Overall Survival in Patients With Metastatic Renal Cell Carcinoma Treated With Vascular Endothelial Growth Factor-Targeted Agents: Results From a Large, Multicenter Study. <i>Journal of Clinical Oncology</i> , 2009, 27, 5794-5799.	0.8	1,751
104	A prospective study of the determinants of exercise in bladder cancer survivors using the Theory of Planned Behavior. <i>Supportive Care in Cancer</i> , 2009, 17, 171-179.	1.0	50
105	The Canadian Uro- Oncology Group multicentre phase II study of docetaxel administered every 3 weeks with prednisone in men with metastatic hormone- refractory prostate cancer progressing after mitoxantrone/prednisone. <i>BJU International</i> , 2008, 102, 551-555.	1.3	12
106	Dr. North's rebuttal. <i>Canadian Urological Association Journal</i> , 2008, 2, 228.	0.3	0
107	L-BLP25: a MUC1-targeted peptide vaccine therapy in prostate cancer. <i>Expert Opinion on Biological Therapy</i> , 2007, 7, 1723-1730.	1.4	30
108	Associations between Exercise and Quality of Life in Bladder Cancer Survivors: A Population-Based Study. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2007, 16, 984-990.	1.1	86

#	ARTICLE	IF	CITATIONS
109	A phase 3 randomized controlled trial of the efficacy and safety of atrasentan in men with metastatic hormone-refractory prostate cancer. <i>Cancer</i> , 2007, 110, 1959-1966.	2.0	276
110	Exercise programming and counseling preferences in bladder cancer survivors: a population-based study. <i>Journal of Cancer Survivorship</i> , 2007, 1, 27-34.	1.5	75
111	Prostate-specific antigen doubling time is associated with survival in men with hormone-refractory prostate cancer. <i>Urology</i> , 2006, 68, 565-569.	0.5	33
112	Vaccination with BLP25 liposome vaccine to treat non-small cell lung and prostate cancers. <i>Expert Review of Vaccines</i> , 2005, 4, 249-257.	2.0	76
113	A multinomial Phase II study of lonafarnib (SCH 66336) in patients with refractory urothelial cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2005, 23, 143-149.	0.8	55
114	The management of malignant pleural effusions in breast cancer. , 2005, , 129-140.		0
115	Matrix metalloproteinase-2 contributes to increased platelet reactivity in patients with metastatic prostate cancer: a preliminary study. <i>Thrombosis Research</i> , 2003, 112, 59-64.	0.8	25
116	A Randomized, Phase III, Double-Blind, Placebo-Controlled Trial of Intrapleural Instillation of Methylprednisolone Acetate in the Management of Malignant Pleural Effusion. <i>Chest</i> , 2003, 123, 822-827.	0.4	15
117	Outcome of advanced stage low grade follicular lymphomas in a population-based retrospective cohort. , 1999, 85, 1361-1368.		8